Allogene Therapeutics updates ALPHA3 trial protocol following safety event

Allogene Therapeutics (ALLO) has announced a significant protocol amendment for its ALPHA3 study evaluating cema-cel for large B-cell lymphoma, discontinuing the lymphodepletion agent ALLO-647 across all trials following a Grade 5 adverse event. The study will now proceed with standard fludarabine and cyclophosphamide (FC) lymphodepletion, with a futility analysis anticipated in H1 2026. While the stock is down 18% and Citizens JMP downgraded it due to development delays, Allogene maintains a strong liquidity position and cash balance, and some analysts retain Buy ratings, citing the potential of other pipeline assets like ALLO-316 and the Dagger Platform Technology.

Analysis

Allogene Therapeutics (NASDAQ:ALLO) has made a significant strategic pivot in its pivotal ALPHA3 study for cema-cel after a Grade 5 adverse event was linked to its proprietary lymphodepletion agent, ALLO-647. The company has discontinued the use of ALLO-647 across all trials and will proceed with the standard fludarabine and cyclophosphamide (FC) regimen, a move made in consultation with the FDA. While this action is presented as a de-risking of the cema-cel program—as the event was deemed unrelated to the therapeutic candidate itself—it introduces a material delay, pushing the next key catalyst, a futility analysis, to the first half of 2026. This delay triggered a downgrade from Citizens JMP to Market Perform and contributed to an 18% decline in the stock price over the past week. Financially, Allogene appears resilient, with a strong liquidity position evidenced by a 9.71 current ratio and a balance sheet holding more cash than debt, which is critical given its significant cash burn. Analyst sentiment is divided; while one firm downgraded on the timeline risk, Citi and H.C. Wainwright reiterated Buy ratings with price targets of $4.00 and $8.00, respectively, pointing to the potential of other pipeline assets like ALLO-316 and the Dagger technology platform. The fact that four analysts have revised earnings upward suggests some underlying optimism about the company's revised strategy, despite the setback.

Key Decisions for Investors

• Investors should re-evaluate their positions based on the extended development timeline for the lead asset cema-cel, as the next major data readout is now delayed until H1 2026, increasing the importance of the company's cash runway.
• The 18% stock decline may present an entry point for those with high risk tolerance, given that the core therapeutic candidate, cema-cel, was not implicated in the adverse event and the company maintains a strong balance sheet.
• It is crucial to assess the value of Allogene's broader pipeline, including the Dagger platform and ALLO-316 for renal cell carcinoma, as the bull case from several analysts now hinges more heavily on these assets offsetting the cema-cel delay.
• Monitor upcoming quarterly reports for the rate of cash burn, as financial endurance has become a more critical factor following the extension of the ALPHA3 trial timeline.